Compare BRBS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | HELP |
|---|---|---|
| Founded | 1893 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.4M | 281.4M |
| IPO Year | 2015 | N/A |
| Metric | BRBS | HELP |
|---|---|---|
| Price | $3.98 | $5.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 234.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 88.64 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.57 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $2.92 | $5.15 |
| 52 Week High | $4.79 | $8.55 |
| Indicator | BRBS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 38.74 |
| Support Level | $3.37 | N/A |
| Resistance Level | $4.10 | $7.28 |
| Average True Range (ATR) | 0.11 | 0.65 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 21.69 | 7.35 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.